EHA 2022: Journaal NHL

Het jaarlijkse congres van de European Hematology Association vond dit jaar in plaats in Wenen. In dit EHA-journaal is dr. Martine Chamuleau te gast om samen met Inge Diepman het belangrijkste congresnieuws op het gebied van non-Hodgkin lymfomen door te nemen.

Het nieuws wordt besproken aan de hand van onderstaande EHA-abstracts:

• Primary results from the phase 3 SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle-cell lymphoma
• Genetic and epigenetic factors driving primary mediastinal B-cell lymphoma pathogenesis and outcome
• R-CODOX-M/R-IVAC versus dose-adjusted(DA)-EPOCH-R in patients with newly diagnosed high-risk Burkitt lymphoma; first results of a multi-center randomized HOVON/SAKK trial.
• Clinical and patient-reported outcomes in a phase 3 study of axicabtagene ciloleucel (axi-cel) vs standard-of-care in elderly patients with relapsed/refractory large B-cell lymphoma (ZUMA-7)
• CAR T-cells associated acute toxicity in B-cell non-Hodgkin lymphoma: real-world study from the DESCART-T registry
• Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: a phase 2 study
• Glofitamab induces durable complete remissions and has favorable safety in patients with relapsed/refractory diffuse large B-cell lymphoma and ≥2 prior therapies: pivotal phase II expansion results

Bekijk hier het volledige overzicht van onze EHA 2022 journaals en interviews.